61 related articles for article (PubMed ID: 21640795)
41. Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Tokuda E; Furukawa Y
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136532
[TBL] [Abstract][Full Text] [Related]
42. Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis.
Pfohl SR; Halicek MT; Mitchell CS
J Neuromuscul Dis; 2015; 2(2):137-150. PubMed ID: 26594635
[TBL] [Abstract][Full Text] [Related]
43. The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis.
Tadic V; Prell T; Lautenschlaeger J; Grosskreutz J
Front Cell Neurosci; 2014; 8():147. PubMed ID: 24910594
[TBL] [Abstract][Full Text] [Related]
44. The role of solvent exclusion in the interaction between D124 and the metal site in SOD1: implications for ALS.
Mera-Adasme R; Suomivuori CM; Fierro A; Pesonen J; Sundholm D
J Biol Inorg Chem; 2013 Dec; 18(8):931-8. PubMed ID: 24026444
[TBL] [Abstract][Full Text] [Related]
45. Exercise induces metallothioneins in mouse spinal cord.
Hashimoto K; Hayashi Y; Inuzuka T; Hozumi I
Neuroscience; 2009 Sep; 163(1):244-51. PubMed ID: 19490933
[TBL] [Abstract][Full Text] [Related]
46. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis.
Cutler RG; Pedersen WA; Camandola S; Rothstein JD; Mattson MP
Ann Neurol; 2002 Oct; 52(4):448-57. PubMed ID: 12325074
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of metallothionein protects cultured motor neurons against oxidative stress, but not mutant Cu/Zn-superoxide dismutase toxicity.
Taylor DM; Minotti S; Agar JN; Durham HD
Neurotoxicology; 2004 Sep; 25(5):779-92. PubMed ID: 15288509
[TBL] [Abstract][Full Text] [Related]
48. Early signs of motoneuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice.
Avossa D; Grandolfo M; Mazzarol F; Zatta M; Ballerini L
Neuroscience; 2006; 138(4):1179-94. PubMed ID: 16442737
[TBL] [Abstract][Full Text] [Related]
49. Disease progression in a transgenic model of familial amyotrophic lateral sclerosis is dependent on both neuronal and non-neuronal zinc binding proteins.
Puttaparthi K; Gitomer WL; Krishnan U; Son M; Rajendran B; Elliott JL
J Neurosci; 2002 Oct; 22(20):8790-6. PubMed ID: 12388585
[TBL] [Abstract][Full Text] [Related]
50. [Abnormal RNA editing and treatment strategy in neurological diseases; towards cure for ALS].
Yamashita T; Kwak S
Seikagaku; 2016 Oct; 88(5):600-8. PubMed ID: 29624324
[No Abstract] [Full Text] [Related]
51. Mutant mouse models of ALS.
Messer A
Neurobiol Aging; 1994; 15(2):247-8. PubMed ID: 7838302
[No Abstract] [Full Text] [Related]
52. Metallothionein-III prevents neuronal death and prolongs life span in amyotrophic lateral sclerosis model mice.
Hashimoto K; Hayashi Y; Watabe K; Inuzuka T; Hozumi I
Neuroscience; 2011 Aug; 189():293-8. PubMed ID: 21640795
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
